Public Release: 

Researchers develop first validated method of detecting drugs of abuse in exhaled breath

Details of new methodology presented in study published in Journal of Chromatography B


Amsterdam, March 9, 2015 -Drug testing is most commonly performed using urine samples. The methodology and regulations for reliable urine testing are well developed and can be considered the current gold standard for drug testing. However, one problem with urine testing is related to the methodology of sample collection, often perceived as inconvenient and privacy-overriding by those undergoing the test. As such, a group of researchers from the Department of Laboratory Medicine at the Karolinska Institute in Sweden have worked on developing a more donor-friendly alternative to urine testing for drugs by focusing on exhaled breath.

Professor Olof Beck, lead researcher of the study, and his team have developed the first fully validated and robust screening method for the routine measurement of drugs of abuse in exhaled breath. The procedure involves a simple method of sample collection and preparation, which is followed by a highly sensitive analytical technique known as LC-MS (Liquid chromatography-mass spectrometry). The drug groups which are identifiable following the technique include: amphetamines, methamphetamines, cannabis, cocaine and heroin.

"The underlying mechanism in exhaled breath drug testing is believed to be the formation of aerosol particles from the airway lining fluid by the breathing process. These aerosol particles may become contaminated with drugs present in the body, which enables drugs to be highlighted. A simple collection device is currently available which selectively collects the micrometer aerosol particles on a filter and enables further laboratory investigation of possible drug content," explained Prof. Beck.

When asked if he could foresee this method of drug testing being used routinely, for example, in roadside tests relating to DUID (Driving Under the Influence of Drugs), Prof. Beck said, "Yes, I see many possible applications of breath drug testing. DUID is only one; workplace, criminal justice, accidents and compliance monitoring of patients are others. For DUID, the short detection time is relevant since the state of influence is in focus, and this combined with the convenient sampling procedure makes it an attractive solution for roadside testing."

Prof. Dr. Rainer Bischoff, University of Groningen added, "As Editor in Chief, I am delighted that Professor Beck and his team of researchers chose to publish his findings in the Journal of Chomatography B. JCB has a long tradition in publishing novel methods with a clear link to biomedical applications. I do hope that implementation of Professor Beck's methodology will help prevent accidents due to illicit drug use and provide a sound basis for drug testing in doping and many other areas."


For more information about this research go to: Elsevier Connect

Article details

"Method validation and application of a liquid chromatography-tandem mass spectrometry method for drugs of abuse testing in exhaled breath" Journal of Chromatography B, Volume 985, 15 March 2015, Pages 189-19, published by Elsevier.

The paper is freely available at:

Author details

Niclas Stephanson (Corresponding author)
Department of Laboratory Medicine,
Section of Clinical Pharmacology,
Karolinska Institutet, Stockholm, Sweden
+46 858583440; +46 858585870.

Olof Beck,
Department of Laboratory Medicine,
Section of Clinical Pharmacology,
Karolinska Institutet, Stockholm, Sweden

About Journal of Chromatography B

The Journal of Chromatography B publishes papers on developments in separation science relevant to biology and biomedical research including both fundamental advances and applications. Analytical techniques which may be considered include the various facets of chromatography, electrophoresis and related methods, affinity and immunoaffinity-based methodologies, hyphenated and other multi-dimensional techniques, and microanalytical approaches. Read more about the journal here:

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey -- and publishes nearly 2,200 journals, including The Lancet and Cell, and over 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries.

Media contact

Darren Sugrue
+31 20 485 3506

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.